Search details
1.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Article
in English
| MEDLINE | ID: mdl-35660812
2.
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.
Br J Haematol
; 181(5): 628-636, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29774521
3.
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
Br J Haematol
; 182(2): 222-230, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29740809
4.
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
Blood
; 127(6): 713-21, 2016 Feb 11.
Article
in English
| MEDLINE | ID: mdl-26631116
5.
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
Br J Haematol
; 179(1): 66-74, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28653400
6.
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Blood
; 123(10): 1461-9, 2014 Mar 06.
Article
in English
| MEDLINE | ID: mdl-24429336
7.
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
Blood
; 122(14): 2331-7, 2013 Oct 03.
Article
in English
| MEDLINE | ID: mdl-23950178
8.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol
; 15(11): 1195-206, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-25242045
9.
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Br J Haematol
; 166(3): 401-9, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-24761838
10.
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits in a kidney allograft.
Am J Kidney Dis
; 63(2): 318-23, 2014 Feb.
Article
in English
| MEDLINE | ID: mdl-24051081
11.
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.
Blood
; 119(15): e131-8, 2012 Apr 12.
Article
in English
| MEDLINE | ID: mdl-22289890
12.
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Blood
; 118(3): 535-43, 2011 Jul 21.
Article
in English
| MEDLINE | ID: mdl-21596852
13.
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Blood
; 116(5): 679-86, 2010 Aug 05.
Article
in English
| MEDLINE | ID: mdl-20385792
14.
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
Eur J Haematol
; 88(1): 1-7, 2012 Jan.
Article
in English
| MEDLINE | ID: mdl-21991938
15.
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Eur J Haematol
; 88(5): 446-9, 2012 May.
Article
in English
| MEDLINE | ID: mdl-22300348
16.
Management of relapsed and relapsed/refractory multiple myeloma.
J Natl Compr Canc Netw
; 9(10): 1209-16, 2011 Oct.
Article
in English
| MEDLINE | ID: mdl-21975917
17.
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Am J Hematol
; 86(7): 573-8, 2011 Jul.
Article
in English
| MEDLINE | ID: mdl-21630305
18.
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.
Cell Rep
; 34(1): 108532, 2021 01 05.
Article
in English
| MEDLINE | ID: mdl-33406420
19.
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Oncology (Williston Park)
; 24(3 Suppl 2): 22-9, 2010 Mar.
Article
in English
| MEDLINE | ID: mdl-20518367
20.
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.
Leukemia
; 34(1): 196-209, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31142847